NEW YORK (GenomeWeb) – Craig-Hallum Capital Group today upgraded shares of Cepheid to a Buy rating, based on recent deals with Quest Diagnostics and Laboratory Corporation of America and an expansion of its product portfolio.

Analyst Bill Bonello upgraded the shares from a previous Hold rating and raised the price target to $75 per share from $52.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Women with breast or ovarian cancer living in medically underserved regions of the US are less likely to get recommended BRCA1 or BRCA2 genetic testing, according to a new study.

Three immunology researchers are to receive this year's Albany Medical Center Prize in Medicine and Biomedical Research, the Albany Times-Union reports.

In Genome Research this week: clonal evolution analysis of acute myeloid leukemia, computational pipeline to examine relationships between bacterial pathogens, and more.

Elephants may have "re-animated" a pseudogene to help stave off cancer, according to the New York Times.